Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 4/2018

21.06.2018 | Laboratory Investigation

Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1

verfasst von: Yoko Akune, Masakazu Yamada, Chika Shigeyasu

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1.

Study design

Cross-sectional study.

Methods

High performance liquid chromatographic (HPLC) method reported for plasma samples was modified for tear samples. Simulated-tear solutions containing lactoferrin, lysozyme and standard solution containing 5-FU or FT were prepared for preliminary measurements. Tear samples from seven patients treated with S-1 were included. The tears were collected following S-1 administration using Schirmer’s strips.

Results

5-FU and FT concentrations of pure standard solution without extraction process were detected as original concentration. However, on extraction, FT samples in simulated-tear solution showed a peak for 5-FU but not for FT. FT was converted to 5-FU in the extraction process. Decomposition from FT to 5-FU was suppressed when 50 mg/mL bovine serum albumin was added during extraction. The mean concentrations of 5-FU and FT in tears during S-1 treatment were 0.17 ± 0.11 and 1.94 ± 0.71 μg/mL, respectively.

Conclusion

A simple HPLC method to determine 5-FU and FT in tear samples was established.
Literatur
1.
Zurück zum Zitat Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed
2.
Zurück zum Zitat Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, et al. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. Anticancer Drugs. 2011;22:811–6.CrossRefPubMed Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, et al. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. Anticancer Drugs. 2011;22:811–6.CrossRefPubMed
3.
Zurück zum Zitat Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T, et al. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One. 2015;10:e0116965.CrossRefPubMedPubMedCentral Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T, et al. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One. 2015;10:e0116965.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000;83:141–5.CrossRefPubMedPubMedCentral Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000;83:141–5.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer—a Japanese trial by the S-1 Cooperative Study Group. Breast Cancer Working Group. Breast Cancer. 2004;11:194–202.CrossRef Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer—a Japanese trial by the S-1 Cooperative Study Group. Breast Cancer Working Group. Breast Cancer. 2004;11:194–202.CrossRef
6.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed
7.
Zurück zum Zitat Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849–55.CrossRefPubMed Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849–55.CrossRefPubMed
8.
Zurück zum Zitat Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000–5.PubMed Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000–5.PubMed
9.
Zurück zum Zitat Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.CrossRefPubMed Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.CrossRefPubMed
10.
Zurück zum Zitat Miao Y, Zhan P, Lv T, Song Y. A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients. Transl Lung Cancer Res. 2015;4:487–97.PubMedPubMedCentral Miao Y, Zhan P, Lv T, Song Y. A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients. Transl Lung Cancer Res. 2015;4:487–97.PubMedPubMedCentral
11.
Zurück zum Zitat Chikama T, Takahashi N, Wakuta M, Nishida T. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis. 2009;15:2896–904.PubMedPubMedCentral Chikama T, Takahashi N, Wakuta M, Nishida T. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis. 2009;15:2896–904.PubMedPubMedCentral
12.
Zurück zum Zitat Kobashi H, Kamiya K, Shimizu K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol. 2011;55:163–5.CrossRefPubMed Kobashi H, Kamiya K, Shimizu K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol. 2011;55:163–5.CrossRefPubMed
14.
Zurück zum Zitat Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140:325–7.CrossRefPubMed Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140:325–7.CrossRefPubMed
15.
Zurück zum Zitat Sasaki T, Miyashita H, Miyanaga T, Yamamoto K, Sugiyama K. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012;56:214–8.CrossRefPubMed Sasaki T, Miyashita H, Miyanaga T, Yamamoto K, Sugiyama K. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012;56:214–8.CrossRefPubMed
16.
Zurück zum Zitat Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065–71.CrossRefPubMed Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065–71.CrossRefPubMed
17.
Zurück zum Zitat Matsumoto Y, Dogru M, Sato EA, Ibrahim OM, Tatematsu Y, Ogawa Y, et al. S-1 induces meibomian gland dysfunction. Ophthalmology. 2010;117(1275):e4–7. Matsumoto Y, Dogru M, Sato EA, Ibrahim OM, Tatematsu Y, Ogawa Y, et al. S-1 induces meibomian gland dysfunction. Ophthalmology. 2010;117(1275):e4–7.
18.
Zurück zum Zitat Mizoguchi S, Okada Y, Kokado M, Saika S. Abnormalities in the meibomian glands in patients with oral administration of anticancer combination drug-capsule TS-1((R)): a case report. BMC Cancer. 2015;15:796.CrossRefPubMedPubMedCentral Mizoguchi S, Okada Y, Kokado M, Saika S. Abnormalities in the meibomian glands in patients with oral administration of anticancer combination drug-capsule TS-1((R)): a case report. BMC Cancer. 2015;15:796.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Sakamoto H, Sakamoto M, Hamada T, Kubota T, Ishibashi T. A case of corneal lesion following treatment by peroras TS-1. Jpn J Clin Ophthalmol. 2008;62:393–8.CrossRef Sakamoto H, Sakamoto M, Hamada T, Kubota T, Ishibashi T. A case of corneal lesion following treatment by peroras TS-1. Jpn J Clin Ophthalmol. 2008;62:393–8.CrossRef
20.
Zurück zum Zitat Zufia L, Aldaz A, Castellanos C, Giraldez J. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Ther Drug Monit. 2003;25:221–8.CrossRefPubMed Zufia L, Aldaz A, Castellanos C, Giraldez J. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Ther Drug Monit. 2003;25:221–8.CrossRefPubMed
21.
Zurück zum Zitat Nassim MA, Shirazi FH, Cripps CM, Veerasinghan S, Molepo MJ, Obrocea M, et al. An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med. 2002;10:513–6.PubMed Nassim MA, Shirazi FH, Cripps CM, Veerasinghan S, Molepo MJ, Obrocea M, et al. An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med. 2002;10:513–6.PubMed
22.
Zurück zum Zitat Buchel B, Rhyn P, Schurch S, Buhr C, Amstutz U, Largiader CR. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr. 2013;27:7–16.CrossRefPubMed Buchel B, Rhyn P, Schurch S, Buhr C, Amstutz U, Largiader CR. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr. 2013;27:7–16.CrossRefPubMed
23.
Zurück zum Zitat Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit. 2009;31:688–94.CrossRefPubMed Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit. 2009;31:688–94.CrossRefPubMed
24.
Zurück zum Zitat Milano G. Dihydropyrimidine dehydrogenase and treatment by fluoropyrimidines-past and future directions. In: Rustum Y, editor. Fluoropyrimidines in cancer therapy. New Jersey: Humana Press; 2003. p. 29–36. Milano G. Dihydropyrimidine dehydrogenase and treatment by fluoropyrimidines-past and future directions. In: Rustum Y, editor. Fluoropyrimidines in cancer therapy. New Jersey: Humana Press; 2003. p. 29–36.
25.
Zurück zum Zitat Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113–22.CrossRefPubMed Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113–22.CrossRefPubMed
26.
Zurück zum Zitat Wu K, Zhang Y. Clinical application of tear proteomics: present and future prospects. Proteom Clin Appl. 2007;1:972–82.CrossRef Wu K, Zhang Y. Clinical application of tear proteomics: present and future prospects. Proteom Clin Appl. 2007;1:972–82.CrossRef
27.
Zurück zum Zitat Jang YH, Sowers LC, Cagin T, Goddard WA 3rd. First principles calculation of pKa values for 5-substituted uracils. J Phys Chem A. 2001;105:274–80.CrossRef Jang YH, Sowers LC, Cagin T, Goddard WA 3rd. First principles calculation of pKa values for 5-substituted uracils. J Phys Chem A. 2001;105:274–80.CrossRef
28.
Zurück zum Zitat Farquharson S, Gift A, Shende C, Inscore F, Ordway B, Farquharson C, et al. Surface-enhanced Raman spectral measurements of 5-fluorouracil in saliva. Molecules. 2008;13:2608–27.CrossRefPubMed Farquharson S, Gift A, Shende C, Inscore F, Ordway B, Farquharson C, et al. Surface-enhanced Raman spectral measurements of 5-fluorouracil in saliva. Molecules. 2008;13:2608–27.CrossRefPubMed
29.
Zurück zum Zitat Bunkute E, Cummins C, Crofts FJ, Bunce G, Nabney IT, Flower DR. PIP-DB: the protein isoelectric point database. Bioinformatics. 2015;31:295–6.CrossRefPubMed Bunkute E, Cummins C, Crofts FJ, Bunce G, Nabney IT, Flower DR. PIP-DB: the protein isoelectric point database. Bioinformatics. 2015;31:295–6.CrossRefPubMed
30.
Zurück zum Zitat Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9:143–4.CrossRefPubMed Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9:143–4.CrossRefPubMed
31.
Zurück zum Zitat Huhtala A, Tӓhti H, Salminen L, Uusitalo H. Evaluation of adverse ocular effects of 5-fluorouracil by using human corneal epithelial cell cultures. J Toxicol Cutan Ocular Toxicol. 2002;21:283–92.CrossRef Huhtala A, Tӓhti H, Salminen L, Uusitalo H. Evaluation of adverse ocular effects of 5-fluorouracil by using human corneal epithelial cell cultures. J Toxicol Cutan Ocular Toxicol. 2002;21:283–92.CrossRef
Metadaten
Titel
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1
verfasst von
Yoko Akune
Masakazu Yamada
Chika Shigeyasu
Publikationsdatum
21.06.2018
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 4/2018
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-018-0603-8

Weitere Artikel der Ausgabe 4/2018

Japanese Journal of Ophthalmology 4/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.